Fintel reports that on April 30, 2025, Leerink Partners downgraded their outlook for Regulus Therapeutics (NasdaqCM:RGLS) ...

Fintel reports that on April 30, 2025, Leerink Partners downgraded their outlook for Quanterix (NasdaqGM:QTRX) from ...

In this article, we will look at the Top 11 Small Cap Stocks to Buy with Biggest Upside Potential.

Leerink notes that Equillium (EQ) announced that the FDA declined to support an accelerated approval pathway for itolizumab in first-line ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

Detailed price information for Molecular Partners Ag ADR (MOLN-Q) from The Globe and Mail including charting and trades.

Fintel reports that on April 30, 2025, Leerink Partners downgraded their outlook for NeoGenomics (BMV:NEO) from Outperform to Market Perform. There are 666 funds or institutions reporting ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

The Cambridge-based biotech company has been trying to reduce operating expenses as it burns cash on its large pipeline.

According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug ...

The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's drug to treat a type of muscle-weakening ...

Leerink lowered the firm’s price target on Thermo Fisher (TMO) to $600 from $625 given lower peer multiples, while keeping an Outperform rating ...